| Kristen H Mills, | |
|
800 N Fant St, Anderson, SC 29621-5708 | |
| (864) 512-1340 | |
| (864) 512-1749 |
| Full Name | Kristen H Mills |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 800 N Fant St, Anderson, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730507716 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 18911 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Anmed Health | Anderson, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anmed Health | 1951215243 | 276 |
| Gastroenterology Associates, Pa | 1951215433 | 60 |
News Archive
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."
› Verified 3 days ago
| Entity Name | Gastroenterology Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487684031 PECOS PAC ID: 1951215433 Enrollment ID: O20031118000794 |
News Archive
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."
› Verified 3 days ago
| Entity Name | Anmed Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710918321 PECOS PAC ID: 1951215243 Enrollment ID: O20031119000738 |
News Archive
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."
› Verified 3 days ago
| Entity Name | Anesthesiology Services Of Anderson Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174513824 PECOS PAC ID: 7517947526 Enrollment ID: O20040721000892 |
News Archive
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."
› Verified 3 days ago
| Entity Name | Amsurg Greenville Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386918795 PECOS PAC ID: 6608038781 Enrollment ID: O20120508000000 |
News Archive
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen H Mills, 800 N Fant St, Anderson, SC 29621-5708 Ph: (864) 512-1417 | Kristen H Mills, 800 N Fant St, Anderson, SC 29621-5708 Ph: (864) 512-1340 |
News Archive
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, announced it has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology.
BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."
› Verified 3 days ago
John C Burgess, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-1340 Fax: 864-512-1749 | |
Amy M. Weaver, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-1340 Fax: 864-512-1749 | |
Brooks C. Cauley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-1340 Fax: 864-512-1749 | |
Joan Schroeder Wortman, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-1000 | |
Mr. Amir Sadri, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-2751 | |
Carol E. Pethel, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 800 N Fant St, Anderson, SC 29621 Phone: 864-512-1340 Fax: 864-512-1749 | |
Michele K. Buckreis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2000 E Greenville St, Anderson, SC 29621 Phone: 864-512-6697 |